ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Renal Phosphate Wasting Disorders: X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO)

This session will include case studies of X-Linked Hypophosphatemia (XLH) as well as diagnosis and management of XLH and Tumor-Induced Osteomalacia (TIO).

  • XLH is a rare, hereditary, progressive, and lifelong skeletal disorder mediated by increased fibroblast growth factor 23 (FGF23) activity that causes renal phosphate wasting. This leads to chronic hypophosphatemia, resulting in poor skeletal, muscular, and dental health and impaired physical function
  • TIO, also known as oncogenic osteomalacia, is an ultrarare, acquired disorder in which tumors that express the phosphaturic hormone FGF23 cause chronic hypophosphatemia, muscle weakness, and osteomalacia
  • Unlike XLH, TIO patients typically have a history of normal phosphate levels and usually present in adulthood with symptoms of pain, muscle weakness, and fatigue that may be severe and progressive